Healthcare - Biotechnology - NASDAQ - US
$ 3.125
-8.89 %
$ 201 M
Market Cap
-2.02
P/E
INCOME STATEMENT
0
REVENUE
-75.6 M
OPERATING INCOME
-71.2 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Inozyme Pharma, Inc.
| Revenue | 0 |
| Cost Of Revenue | 1.29 M |
| Gross Profit | -1.29 M |
| Operating Expenses | 75.6 M |
| Operating Income | -75.6 M |
| Other Expenses | -4.48 M |
| Net Income | -71.2 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 1.3 | 1.2 | 1.1 | 0.2 | 83 K | 26 K |
| Gross Profit | (1.3) | (1.2) | (1.1) | (0.2) | 83 K | 26 K |
| OPERATING INCOME | ||||||
| Operating Expenses | 75.6 | 68.7 | 56.6 | 57.0 | 20.8 | 11.6 |
| Selling, General and Administrative Expenses | 20.8 | 20.8 | 18.9 | 10.5 | 4.6 | 3.5 |
| Research and Development Expenses | 54.8 | 47.8 | 37.7 | 46.5 | 16.2 | 8.1 |
| Operating Income | (75.6) | (68.7) | (56.6) | (57.0) | (20.8) | (11.6) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 3.3 | (1.6) | 0 | 0 | 0 | 0 |
| Total Other Income | 4.5 | 1.6 | 22 K | 0.6 | 1.1 | 4.6 |
| Pre-Tax Income | (71.2) | (67.1) | (56.6) | (56.4) | (19.7) | (7.0) |
| NET INCOME | ||||||
| Tax Provision | 0 | (1.6) | (0.2) | (0.6) | (1.1) | 4.6 |
| Net Income | (71.2) | (65.4) | (56.4) | (55.8) | (18.6) | (7.0) |
| EPS | 1.37 | 1.73 | 2.39 | 2.39 | 1.23 | 0.46 |